NHS to Roll Out Wegovy for 1.2 Million at Risk of Heart Attacks and Strokes

NHS to Offer Wegovy to 1.2 Million for Heart Risk Reduction

In a major step forward for public health, NHS England has confirmed that 1.2 million individuals with cardiovascular disease will soon be eligible for a groundbreaking treatment known as Wegovy (semaglutide). Set to be available from this summer, the drug aims to lower the risk of heart attacks and strokes among those who are overweight or obese and have previously experienced a heart attack, stroke, or serious circulation issues in the legs, such as peripheral arterial disease NHS England.

Wegovy, a GLP-1 receptor agonist, is administered as a weekly injection and will be prescribed alongside recommendations for a healthy diet and increased physical activity. The treatment targets individuals with a body mass index (BMI) of 27 or higher who have a history of cardiovascular events. Clinical trial data has demonstrated that semaglutide can reduce the risk of serious heart problems by 20% in this group compared to a placebo, offering a significant protective effect NHS England.

The National Institute for Health and Care Excellence (NICE) has issued draft guidance approving the use of semaglutide for this purpose, following a cost-effective deal struck by the NHS to make the treatment viable for widespread use. This builds on the drug’s existing availability within the NHS for obesity management through specialist weight management services and under the brand name Ozempic for type 2 diabetes treatment NHS England.

Helen Williams, National Clinical Director for Cardiovascular Disease Prevention at NHS England, described the rollout as potentially life-changing for over a million people at high risk of further cardiovascular events. “We know that people who have already had a heart attack or stroke face a much higher risk of having another,” she said. “Used alongside a healthy diet and regular exercise, semaglutide could help prevent thousands of future major cardiovascular events and give many people the chance at a longer and healthier life” NHS England.

This initiative forms part of the NHS’s broader 10-Year Health Plan, which focuses on enabling people to live well with long-term conditions, avoiding serious complications, and reducing preventable hospital admissions or deaths. The NHS has already seen success with other cardiovascular interventions, such as faster access to blood-thinning medicines, which have helped over 500,000 people and prevented thousands of strokes and deaths. Blood pressure and cholesterol-lowering medications are also supporting millions in managing heart health NHS England.

Cardiovascular disease remains a significant public health challenge, though NHS England notes that around 7 in 10 cases are preventable. The introduction of Wegovy for this high-risk group represents a proactive approach to tackling one of the leading causes of morbidity and mortality in England. It complements other ongoing efforts to improve heart health outcomes through innovative treatments and preventative strategies NHS England.

While the announcement marks a significant advancement, detailed information on the exact timeline for the rollout and specific access criteria beyond BMI and cardiovascular history remains limited in the available sources. Further updates from NHS England will likely clarify how patients can access the treatment and the capacity of the health service to deliver it at scale. For now, this development signals a promising new tool in the fight against cardiovascular disease, with the potential to transform lives for many across England NHS England.

As the NHS continues to navigate other challenges, including industrial action by resident doctors and record demand in A&E services, the focus on preventative care through treatments like Wegovy underscores a commitment to long-term health improvements despite immediate operational pressures. Patients and healthcare providers alike will be watching closely as this programme unfolds in the coming months.